Highlight Therapeutics SL

Highlight Therapeutics SL is a dynamic biotechnology company committed to pioneering advancements in immuno-oncology. Highlight Therapeutics focuses on developing innovative therapies that harness the power of the immune system to combat cancer. With a robust research and development pipeline, Highlight Therapeutics SL is dedicated to creating groundbreaking treatments that improve patient outcomes and transform the landscape of cancer care.

Highlight Therapeutics' lead drug candidate, BO-112, is at the forefront of their therapeutic approach. This RNA-based therapy is designed to stimulate a strong immune response, converting 'cold' tumors into 'hot' tumors, making them more susceptible to the immune system's attack. Highlight Therapeutics SL aims to provide effective solutions for patients who may not respond to current checkpoint inhibitor therapies. Clinical trials are ongoing to explore the potential of BO-112 as a monotherapy and in combination with other treatments.

Based in Valencia, ES, Highlight Therapeutics is driven by a passion for innovation and a commitment to excellence. The company collaborates with external partners, including Merck & Co and UCLA, to further accelerate the development of its groundbreaking therapies. Highlight Therapeutics SL is poised to make a significant impact in the field of immuno-oncology. We invite the manager of Highlight Therapeutics SL to create a customized and exclusive company showcase and product listing on our platform.